(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about the effectiveness of Lilly s Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies COVID-19 PRS Test, Adamis SYMJEPI products being made available in the Walgreens Prescription Savings Club, Fluidigm s Advanta Dx SARS-CoV-2 RT-PCR Assay receiving the CE-IVD mark.
Read on.
1. Adamis to Offer SYMJEPI in Walgreens Prescription Savings Club
Adamis Pharmaceuticals Corporation (ADMP) surged more than 90% in after-hours Thursday, on news of its SYMJEPI products now being available to members of the Walgreens Prescription Savings Club program.
Share this article
Share this article
TORONTO, Jan. 21, 2021 /CNW/ - Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) – enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.
The 965 participants who tested negative for the SARS-CoV-2 virus at baseline (299 residents and 666 staff) were included in the analysis of primary and key secondary endpoints for assessing bamlanivimab as a preventative, while the 132 participants (41 residents and 91 staff) who tested positive for the virus at baseline were included in ex
Health experts have a reminder as nearly 260,000 Connecticut residents get COVID-19 vaccines. “We’re not going to be able to let up on mask wearing or.
What is Monoclonal Antibody Therapy? Eli Lilly Says Treatment Prevents COVID Infection
On 1/22/21 at 7:02 AM EST
But what does monoclonal antibody therapy involve?
Antibodies are proteins that the immune system produces to fight viruses, like SARS-CoV-2 which causes COVID-19. Monoclonal antibodies are produced in a lab but they function in much the same way as the ones found in the body naturally.
Read more
Therapies have now been developed that use the lab-made antibodies to treat people who have tested positive for COVID-19 and have mild to moderate symptoms.
To date, the Food and Drug Administration (FDA) has authorized two such treatments for emergency use: casirivimab and imdevimab given together, and bamlanivimab administered on its own.
A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.